Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1974 1
1982 1
1986 2
1988 2
1989 1
1990 2
1991 1
1992 2
1993 1
1994 3
1995 3
1996 4
1997 1
1998 2
1999 3
2000 1
2001 2
2003 3
2004 5
2005 6
2006 6
2007 3
2008 6
2009 7
2010 7
2011 5
2012 4
2013 5
2014 5
2015 15
2016 10
2017 11
2018 13
2019 13
2020 20
2021 8
2022 14
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean g crompton[Author] (113 results)?
Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer.
Carrot-Zhang J, Chambwe N, Damrauer JS, Knijnenburg TA, Robertson AG, Yau C, Zhou W, Berger AC, Huang KL, Newberg JY, Mashl RJ, Romanel A, Sayaman RW, Demichelis F, Felau I, Frampton GM, Han S, Hoadley KA, Kemal A, Laird PW, Lazar AJ, Le X, Oak N, Shen H, Wong CK, Zenklusen JC, Ziv E; Cancer Genome Atlas Analysis Network; Cherniack AD, Beroukhim R. Carrot-Zhang J, et al. Among authors: frampton gm. Cancer Cell. 2020 May 11;37(5):639-654.e6. doi: 10.1016/j.ccell.2020.04.012. Cancer Cell. 2020. PMID: 32396860 Free PMC article.
Mechanisms and therapeutic implications of hypermutation in gliomas.
Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, Cortes-Ciriano I, Birzu C, Geduldig JE, Pelton K, Lim-Fat MJ, Pal S, Ferrer-Luna R, Ramkissoon SH, Dubois F, Bellamy C, Currimjee N, Bonardi J, Qian K, Ho P, Malinowski S, Taquet L, Jones RE, Shetty A, Chow KH, Sharaf R, Pavlick D, Albacker LA, Younan N, Baldini C, Verreault M, Giry M, Guillerm E, Ammari S, Beuvon F, Mokhtari K, Alentorn A, Dehais C, Houillier C, Laigle-Donadey F, Psimaras D, Lee EQ, Nayak L, McFaline-Figueroa JR, Carpentier A, Cornu P, Capelle L, Mathon B, Barnholtz-Sloan JS, Chakravarti A, Bi WL, Chiocca EA, Fehnel KP, Alexandrescu S, Chi SN, Haas-Kogan D, Batchelor TT, Frampton GM, Alexander BM, Huang RY, Ligon AH, Coulet F, Delattre JY, Hoang-Xuan K, Meredith DM, Santagata S, Duval A, Sanson M, Cherniack AD, Wen PY, Reardon DA, Marabelle A, Park PJ, Idbaih A, Beroukhim R, Bandopadhayay P, Bielle F, Ligon KL. Touat M, et al. Among authors: frampton gm. Nature. 2020 Apr;580(7804):517-523. doi: 10.1038/s41586-020-2209-9. Epub 2020 Apr 15. Nature. 2020. PMID: 32322066 Free PMC article.
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma.
Gounder MM, Agaram NP, Trabucco SE, Robinson V, Ferraro RA, Millis SZ, Krishnan A, Lee J, Attia S, Abida W, Drilon A, Chi P, Angelo SP, Dickson MA, Keohan ML, Kelly CM, Agulnik M, Chawla SP, Choy E, Chugh R, Meyer CF, Myer PA, Moore JL, Okimoto RA, Pollock RE, Ravi V, Singh AS, Somaiah N, Wagner AJ, Healey JH, Frampton GM, Venstrom JM, Ross JS, Ladanyi M, Singer S, Brennan MF, Schwartz GK, Lazar AJ, Thomas DM, Maki RG, Tap WD, Ali SM, Jin DX. Gounder MM, et al. Among authors: frampton gm. Nat Commun. 2022 Jun 15;13(1):3406. doi: 10.1038/s41467-022-30496-0. Nat Commun. 2022. PMID: 35705558 Free PMC article.
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.
Lee JK, Sivakumar S, Schrock AB, Madison R, Fabrizio D, Gjoerup O, Ross JS, Frampton GM, Napalkov P, Montesion M, Schutzman JL, Ye X, Hegde PS, Nagasaka M, Oxnard GR, Sokol ES, Ou SI, Shi Z. Lee JK, et al. Among authors: frampton gm. NPJ Precis Oncol. 2022 Dec 9;6(1):91. doi: 10.1038/s41698-022-00334-z. NPJ Precis Oncol. 2022. PMID: 36494601 Free PMC article.
Inebilizumab: First Approval.
Frampton JE. Frampton JE. Drugs. 2020 Aug;80(12):1259-1264. doi: 10.1007/s40265-020-01370-4. Drugs. 2020. PMID: 32729016 Free PMC article. Review.
In June 2020, inebilizumab received its first global approval in the USA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are seropositive for immunoglobulin G autoantibodies against aquaporin-4 (AQP4-IgG). The drug is also undergoi …
In June 2020, inebilizumab received its first global approval in the USA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) …
Degarelix.
Frampton JE, Lyseng-Williamson KA. Frampton JE, et al. Drugs. 2009 Oct 1;69(14):1967-76. doi: 10.2165/10484080-000000000-00000. Drugs. 2009. PMID: 19747011
Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that, in common with GnRH receptor agonists (e.g. leuprolide, goserelin and triptorelin), is indicated for use as an androgen-deprivation therapy in patients with advanced prostate cancer. ...Degareli …
Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that, in common with GnRH receptor agonists (e.g. leuprolide …
Tigecycline.
Frampton JE, Curran MP. Frampton JE, et al. Drugs. 2005;65(18):2623-35; discussion 2636-7. doi: 10.2165/00003495-200565180-00008. Drugs. 2005. PMID: 16392879 Review.
In well designed, pivotal phase III studies, tigecycline monotherapy was noninferior to combination therapy with vancomycin 1 g plus aztreonam 2 g every 12 hours in hospitalised adult patients with cSSSIs (two trials; pooled clinical cure rates, 86.5% vs 88.6%) or b …
In well designed, pivotal phase III studies, tigecycline monotherapy was noninferior to combination therapy with vancomycin 1 g plus …
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert EM, Bourque D, O'Connell C, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Alpha-Cobb G, Guria A, He J, Frank S, Nunnally AC, Bailey M, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller VA. Singal G, et al. Among authors: frampton gm. JAMA. 2019 Apr 9;321(14):1391-1399. doi: 10.1001/jama.2019.3241. JAMA. 2019. PMID: 30964529 Free PMC article.
Vinflunine.
Frampton JE, Moen MD. Frampton JE, et al. Drugs. 2010 Jul 9;70(10):1283-93. doi: 10.2165/11204970-000000000-00000. Drugs. 2010. PMID: 20568834 Review.
The most frequent treatment-related adverse events in vinflunine recipients included myelosuppression (e.g. neutropenia) and gastrointestinal symptoms (e.g. constipation). ...
The most frequent treatment-related adverse events in vinflunine recipients included myelosuppression (e.g. neutropenia) and gastroin …
200 results